Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25419509 | 1.00 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1KMT2A | |
| SCHEMBL15776693 | 1.00 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1KMT2A | |
| SCHEMBL24251635 | 0.95 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1KMT2A | |
| SCHEMBL23891826 | 0.93 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1KMT2A | |
| SCHEMBL14470269 | 0.93 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1KMT2A | |
| SCHEMBL17921382 | 0.93 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1KMT2A | |
| SCHEMBL15982310 | 0.92 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1KMT2A | |
| SCHEMBL26331756 | 0.92 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1KMT2A | |
| SCHEMBL23891709 | 0.90 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1KMT2A | |
| SCHEMBL3569051 | 0.89 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009915-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2025-01-09 | — | — | US | disclosed |
| US-20240066156-A1 | Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2024-02-29 | — | — | US | disclosed |
| US-20230398239-A1 | Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-12-14 | — | — | US | disclosed |
| US-20230310610-A1 | Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-10-05 | — | — | US | disclosed |
| EP-4249471-A2 | PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM Corporation (JP) | 2023-09-27 | — | — | EP | disclosed |
| EP-3929196-B1 | PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORP (JP) | 2023-08-23 | — | — | EP | disclosed |
| EP-3929196-B1 | PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORP (JP) | 2023-08-23 | — | — | EP | disclosed |
| US-11730834-B2 | Targeted radiotherapy chelates for in situ immune modulated cancer vaccination | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| US-9446157-B2 | Chelated PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446157-B2 | Chelated PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160199520-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
| US-20140241985-A1 | Chelated PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140241985-A1 | Chelated PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2014-08-28 | — | — | US | disclosed |
| EP-1806350-A2 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | BRACCO International B.V. (NL) | 2007-07-11 | — | — | EP | disclosed |
| EP-1153029-B1 | AMPHIPATIC POLYCARBOXYLIC CHELATES AND COMPLEXES WITH PARAMAGNETIC METALS AS MRI CONTRAST AGENTS | BRACCO INT BV (NL) | 2007-01-10 | — | — | EP | disclosed |
| US-6652834-B2 | Tensioactive properties, long lasting activity in the blood pool | BRACCO INTERNATIONAL B.V. (NL) | 2003-11-25 | — | — | US | disclosed |
| US-20020098152-A1 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | BRACCO INTERNATIONAL B.V. | 2002-07-25 | — | — | US | disclosed |
| US-6342598-B1 | BLOOD-POOL CONTRAST AGENTS OF OUTSTANDING LONG LIFE IN CIRCULATION | BRACCO INTERNATIONAL B.V. (NL) | 2002-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | SLC39A3, SLC39A14, SLC39A11 | ALDH1A1 3098/4885SMN1; SMN2 2614/4885MAPK1 384/4885 |
| US-20020098152-A1 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | SLC39A14, HAMP, PICALM | ALDH1A1 4599/4885SMN1; SMN2 2228/4885MAPK1 3435/4885 |
| US-11730834-B2 | Targeted radiotherapy chelates for in situ immune modulated cancer vaccination | CD47, STING1, ARG1 | ALDH1A1 2324/4885SMN1; SMN2 1398/4885MAPK1 2295/4885 |
| US-20230398239-A1 | Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies | CD274, CD47, PDCD1 | ALDH1A1 3521/4885SMN1; SMN2 1561/4885MAPK1 985/4885 |
| US-20240066156-A1 | Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination | CD47, STING1, ARG1 | ALDH1A1 2324/4885SMN1; SMN2 1398/4885MAPK1 2295/4885 |
| US-20160199520-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | SLC39A3, SLC39A14, SLC39A11 | ALDH1A1 3116/4885SMN1; SMN2 2615/4885MAPK1 393/4885 |
| US-20230310610-A1 | Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents | H1-2, H1-3, H1-0 | ALDH1A1 3582/4885SMN1; SMN2 2598/4885MAPK1 1930/4885 |
| US-20140241985-A1 | Chelated PSMA Inhibitors | FOLH1, KLK3, PSMA1 | ALDH1A1 1059/4885SMN1; SMN2 3881/4885MAPK1 3334/4885 |
| US-20250009915-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | SLC39A3, SLC39A14, SLC39A11 | ALDH1A1 3116/4885SMN1; SMN2 2615/4885MAPK1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.